Drugs / Conjugated bile acids sodium
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02871882 Comparator | Sep 2016 → Oct 2017 | obesity disorder, type 2 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conjugated bile acids sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871882 ↗ |
| Known as | IC-CBAS | “In a placebo-controlled, double-blind, randomised, 28-day trial, we studied the effect of ileo-colonic delivery of conjugated BAs (IC-CBAS) on glucose metabolism, incretins,...” PMID 32344198 ↗ Apr 2020 |
| Route | Oral | “500 mg tablets taken orally twice daily for 28 (+/- 4) days” NCT02871882 ↗ |